Estrogen receptor in malignant melanoma.

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• The role of estrogen receptor (ER) in malignant melanoma prognosis is debated.
• Estrogen binding protein (ER) presence and its impact on melanoma progression require further investigation.

Purpose of the Study:

• To prospectively evaluate the incidence of ER in malignant melanoma patients.
• To correlate ER status with established prognostic variables and patient survival outcomes.

Main Methods:

• Prospective assay for ER in 141 malignant melanoma patients.
• Correlation analysis of ER presence with prognostic factors including disease-free interval, survival, and recurrence.
• Cox multivariate analysis to determine ER's significance in survival.

Main Results:

• Overall ER incidence was 43%, with higher rates in females (50%) vs. males (38.7%).
• ER-positive (ER+) melanoma patients exhibited significantly longer disease-free intervals and survival compared to ER-negative (ER-) patients.
• ER status was identified as a significant prognostic variable for survival, alongside tumor thickness and nodal status.

Conclusions:

• Estrogen receptor (ER) status may serve as a predictive marker for a less aggressive, more indolent form of malignant melanoma.
• The findings suggest ER positivity is associated with improved survival outcomes in melanoma patients, particularly women with extremity lesions.